Browse > Article

Antigenicity of HM10760 in Guinea Pigs  

Choi, Woo-Hyuck (Korea Institute of Toxicology)
Lee, Sung-Hak (Korea Institute of Toxicology)
Lee, Mi-Chael (Korea Institute of Toxicology)
Chung, Moon-Ku (Korea Institute of Toxicology)
Kwon, Se-Chang (Research Center, Hanmi Pharm Co.)
Lee, Gwan-Sun (Research Center, Hanmi Pharm Co.)
Han, Jae-Yong (School of Agricultural Biotechnology, Seoul National University)
Koh, Woo-Suk (Korea Institute of Toxicology)
Publication Information
Toxicological Research / v.21, no.3, 2005 , pp. 241-247 More about this Journal
Abstract
HM10760 is a recombinant human erythropoietin that has beer developed as a drug for anemia. In this study, antigenic potential of HM10760 was examined by active systemic anaphylaxis in guinea pigs and passive cutaneous anaphylaxis in a guinea pig-guinea pig system. HM10760 was subcutaneously administered at 0, 2, and $20{\mu}g/kg$ and also as a suspension with adjuvant ($20{\mu}g/kg$ + FCA). Ovalbumin as a suspension with adjuvant was administered to induce positive control responses. In the active systemic anaphylaxis test, no symptoms except rubbing or licking nose and urination that were considered as physiological phenomena were observed at $0{\mu}g/kg$. Four of 5 animals at $2{\mu}g/kg$ and all the 5 animals at $20{\mu}g/kg$ showed cyanosis and lying on side. All animals in the adjuvant mixture group showed relatively mild symptoms such as rubbing or licking nose, urination, and evacuation. In the passive cutaneous anaphylaxis test, 0/5, 3/5, and 5/5 serum samples from the animals immunized with 0, 2, and $20{\mu}g/kg$, respectively, showed positive reactions against HM10760. All 5 sera collected from the animals immunized with an adjuvant mixture contained HM10760-specific antibodies. These results suggest HM10760 have antigenicity in guinea pigs.
Keywords
Erythropoietin; Antigenicity; Active systemic anaphylaxis; Passive cutaneous anaphylaxis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Bitonti, A.J., Dumont, .J.A., Low, S.C., Peters, R.T., Kropp, K.E., Palombella, V.J. Stattel, J.M., Lu, Y, Tan, C.A., Song, J.J., Garcia, A.M., Simister, N.E., Spiekermann, G.M., Lencer, W.I. and Blumberg, R.S. (2004): Pulmonary delivery of an erythropoietin Fc fusion protein in nonhuman primates through an immunoglobulin transport pathway. Proc. Natl. Acad. Sci. USA, 101, 9763-9768   DOI   ScienceOn
2 Goldwasser, E., Kung, C.K. and Eliason, J. (1974): On the mechanism of erythropoietin-induced differentiation. 13. The role of sialic acid in erythropoietin action. J. Biol. Chem., 249, 4202-4206
3 Kang, K.K., Cho, H., Baik, N.G. and Kim W.B. (1998): Antigenicity study of recombinant human erythropoietin. J. Appl. Pharmacol., 6, 50-55   과학기술학회마을
4 Osterborg, A. (2004): New erythropoietic proteins: rationale and clinical data. Semin. Oncol., 3, 12-18   DOI   PUBMED   ScienceOn
5 Way, J.C., Lauder, S., Brunkhorst, B., Kong, S.M., Qi, A., Webster, G., Campbell, I., McKenzie, S., Lan, Y., Marelli, B., Nguyen, L.A., Degon, S., Lo, K.M. and Gillies, S.D. (2005): Improvement of Fe-erythropoietin structure and pharmacokinetics by modification at a disulfide bond. Protein Eng. Des. Sel., 18, 111-118   DOI   ScienceOn
6 Glodberg, M.A. and Schneider, T.J. (1994): Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J. BioI. Chem., 269, 4355-4359
7 Gershon, S.K., Luksenburg, H., Cote, T.R. and Braun, M.M. (2002): Pure red cell aplasia and recombinant erythropoietin. N. Engl. J. Med., 346,1584-1586   DOI   ScienceOn
8 Mota, I. and Wong, D. (1969): Homologous and heterologous passive cutaneous anaphylatic activity of mouse antisera during the course of immunization. Life. Sci., 8, 813-820   DOI   PUBMED   ScienceOn
9 Macdougall, I.C. (2005): Antibody-mediated pure cell aplasia (PRCA): epidemiology, immunogenicity and risks. Nephrol. Dial. Transplant., 20, iv9-15   DOI   ScienceOn
10 Morell, A.G, Irvine, R.A, Sternlieb, I., Scheinberg, I.H. and Ashwell, G (1968): Physical and chemical studies on ceruloplasmin. V. Metabolic studies on sialic acid-free ceruloplasmin in vivo. J. BioI. Chem., 243, 155-159
11 Saito, T., Urabe, A. and Takaku, F. (1984): in vitro assay of erythropoietin: simple determination in a small amount of human serum samples. Jpn. J. Med., 23, 16-21   DOI
12 Karol, M.H. and Graham, C. (1997): Antibody-mediated hypersensitivity. in [Comprehensive toxicology; Ed. Lawrence D.A., vol. 5 (Toxicology of the immune system)], Pergamon Press, New York, pp. 305-322.
13 Sytkowski, A.J., Lunn, E.D., Risinger, MA and Davis, K.L. (1999): An erythropoietin fusion protein comprised of identical repeating domains exhibits enhanced biological prop- erties. J. Bioi. Chem., 274, 24773-24778   DOI
14 Cooper, J.C., Morgan, G, Harding, S., Subramanyam, M., Majeau, G.R, Moulder, K. and Alexander, D.R. (2003): Alefacept selectively promotes NK cell-mediated deletion of CD45R0+ human T cells. Eur J. Immunol., 33, 666-675   DOI   ScienceOn
15 Eschbach, J.W, Egrie, J.C., Downing, M.R., Browne, J.K and Adamson, J.W. (1987): Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N. Engl. J. Med., 316, 73-78   DOI   ScienceOn
16 Wallner, S.F., Kurnick, J.E., Vautrin, R.M., White, M.J., Chapman, R.G. and Ward, H.P. (1977): Levels of erythropoietin in patients with the anemias of chronic diseases and liver failure. Am. J. Hematol., 3, 37-44   DOI